Karina D Steffensen
Overview
Explore the profile of Karina D Steffensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rietjens J, Griffioen I, Sierra-Perez J, Sroczynski G, Siebert U, Buyx A, et al.
Palliat Care Soc Pract
. 2024 Feb;
18:26323524231225249.
PMID: 38352191
Background: Patients with cancer often have to make complex decisions about treatment, with the options varying in risk profiles and effects on survival and quality of life. Moreover, inefficient care...
2.
Birkelund L, Dieperink K, Sodemann M, Lindell J, Steffensen K, Nielsen D
J Health Commun
. 2024 Jan;
29(3):187-199.
PMID: 38294170
We use language to achieve understanding, and language barriers can have major health consequences for patients with serious illness. While ethnic minorities are more likely to experience social inequalities in...
3.
You B, Sehgal V, Hosmane B, Huang X, Ansell P, Dinh M, et al.
J Clin Oncol
. 2022 Jul;
41(1):107-116.
PMID: 35867965
Purpose: In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas. We...
4.
Faaborg L, Jakobsen A, Waldstrom M, Petersen C, Andersen R, Steffensen K
Biomark Med
. 2021 Sep;
15(15):1309-1317.
PMID: 34514844
In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a...
5.
Aghajanian C, Bookman M, Fleming G, Swisher E, Steffensen K, Friedlander M, et al.
Gynecol Oncol
. 2021 Jun;
162(2):375-381.
PMID: 34112513
Objective: In the phase 3 VELIA/GOG-3005 trial, veliparib added to carboplatin-paclitaxel and continued as maintenance improved progression-free survival (PFS) compared to carboplatin-paclitaxel alone in patients with newly diagnosed ovarian carcinoma....
6.
Jakobsen A, Andersen R, Hansen T, Jensen L, Faaborg L, Steffensen K, et al.
Eur J Cancer
. 2021 Apr;
149:128-133.
PMID: 33857886
Aim: The aim of the study was to compare ctDNA response rate and objective response rate as surrogate markers for overall survival (OS) in patients with metastatic cancer treated with...
7.
Sondergaard S, Madsen P, Hilberg O, Bechmann T, Jakobsen E, Jensen K, et al.
Patient Educ Couns
. 2021 Jan;
104(7):1560-1567.
PMID: 33390303
Objective: Concerns of increased time consumption and of the impact on clinical decisions may restrain doctors from shared decision making (SDM). This paper evaluates consultation length and decisions made when...
8.
Gultekin M, Ak S, Ayhan A, Strojna A, Pletnev A, Fagotti A, et al.
Cancer Med
. 2020 Nov;
10(1):208-219.
PMID: 33205595
Background: The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the...
9.
Abildgaard C, Do Canto L, Steffensen K, Rogatto S
Front Oncol
. 2020 Feb;
9:1549.
PMID: 32039022
Ovarian cancer (OC) accounts for more than 150,000 deaths worldwide every year. Patients are often diagnosed at an advanced stage with metastatic dissemination. Although platinum- and taxane-based chemotherapies are effective...
10.
Riis C, Jensen P, Bechmann T, Moller S, Coulter A, Steffensen K
Acta Oncol
. 2020 Feb;
59(4):444-452.
PMID: 32000559
The population of breast cancer survivors is increasing as a positive consequence of early detection and enhanced treatment. The disease and treatment associated side-effects or late-effects often impact on quality...